Astellas Pharma Inc.
R&D Meeting
March 9, 2022
Event Summary
[Company Name] | Astellas Pharma Inc. | |
[Company ID] | 4503-QCODE | |
[Event Language] | JPN | |
[Event Type] | Investor Conference | |
[Event Name] | R&D Meeting | |
[Date] | March 9, 2022 | |
[Time] | 09:30 - 11:05 | |
(Total: 95 minutes, Presentation: 58 minutes, Q&A: 37 minutes) | ||
[Venue] | Webcast | |
[Number of Speakers] | 5 | |
Kenji Yasukawa | Representative Director, President and CEO | |
Mathew Pletcher | Division Head of GT-RTO | |
Bernhardt Zeiher | Chief Medical Officer | |
Naoki Okamura | Chief Strategy Officer (CStO), Chief Business | |
Officer (CBO) | ||
Yoshitsugu Shitaka | Corporate Executive, Chief Scientific Officer | |
[Participant Names] | Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |
Kazuaki Hashiguchi | Daiwa Securities Co. Ltd. | |
Motoya Kohtani | Nomura Securities Co., Ltd. | |
Madoka Sato | Schroder Investment Management (Japan) | |
Limited |
Support | |||
Japan | 03.4405.3160 | North America | 1.800.674.8375 |
Tollfree | 0120.966.744 | Email Support | support@scriptsasia.com |
1
Presentation
Yasukawa: Good morning, everyone. I'm Kenji Yasukawa of Astellas Pharma Inc. Thank you very much for joining our R&D Meeting despite your very busy schedule today. In our R&D Meeting today, we are going to explain Astellas' initiatives for gene therapy.
This is a cautionary statement regarding forward-looking information on page two. I'm not going to read it.
Support | |||
Japan | 03.4405.3160 | North America | 1.800.674.8375 |
Tollfree | 0120.966.744 | Email Support | support@scriptsasia.com |
2
Page 3. This is the agenda for today.
Support | |||
Japan | 03.4405.3160 | North America | 1.800.674.8375 |
Tollfree | 0120.966.744 | Email Support | support@scriptsasia.com |
3
Page 4.
Support | |||
Japan | 03.4405.3160 | North America | 1.800.674.8375 |
Tollfree | 0120.966.744 | Email Support | support@scriptsasia.com |
4
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Astellas Pharma Inc. published this content on 10 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 March 2022 07:52:00 UTC.